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Avian inﬂ  uenza virus (H5N1) can be transmitted to hu-
mans, resulting in a severe or fatal disease. The aim of this 
study was to evaluate the immune cross-reactivity between 
human and avian inﬂ  uenza (H5N1) strains in healthy donors 
vaccinated for seasonal inﬂ  uenza A (H1N1)/(H3N2). A small 
frequency of CD4 T cells speciﬁ  c for subtype H5N1 was de-
tected in several persons at baseline, and seasonal vaccine 
administration enhanced the frequency of such reactive CD4 
T cells. We also observed that seasonal vaccination is able 
to raise neutralizing immunity against inﬂ  uenza (H5N1) in a 
large number of donors. No correlation between inﬂ  uenza-
speciﬁ  c CD4 T cells and humoral responses was observed. 
N1 may possibly be a target for both cellular and humoral 
cross-type immunity, but additional experiments are needed 
to clarify this point. These ﬁ  ndings highlight the possibility of 
boosting cross-type cellular and humoral immunity against 
highly pathogenic avian inﬂ  uenza A virus subtype H5N1 by 
seasonal inﬂ  uenza vaccination.
I
nﬂ   uenza viruses are segmented, negative-sense RNA 
viruses belonging to the family Orthomyxoviridae. Ac-
cording to the antigenic differences in nucleoprotein and 
matrix proteins, 3 types of inﬂ  uenza viruses (A, B, and C) 
have been described. Inﬂ  uenza viruses A and B are associ-
ated with seasonal illness and death, whereas inﬂ  uenza virus 
C causes mild infections (1,2). Inﬂ  uenza A viruses are sub-
typed on the basis of the antigenic differences on external 
hemagglutinin (HA) and neuraminidase (NA) glycoproteins. 
Human type A inﬂ  uenza virus subtypes have been limited to 
H1, H2, and H3 and to N1 and N2 (3). Several HAs and NAs 
have been isolated from avian hosts; occasionally, they have 
been associated with human outbreaks (4,5).
Cytotoxic T lymphocytes play a central role in the 
clearance of primary inﬂ  uenza virus infection, peaking af-
ter 7–10 days; the peak in antibody titers occurs 4–7 weeks 
after primary infection (6–8). Neutralizing antibodies are 
completely protective against secondary challenges only 
with closely related strains, but they are ineffective against 
viruses with major antigenic divergence. For this reason, 
current inﬂ  uenza vaccines are prepared annually on the 
basis of World Health Organization forecasts on the most 
probable inﬂ  uenza A and B virus strains thought to be cir-
culating in the next seasonal outbreak (5,7). By contrast, 
cellular responses to cross-reactive epitopes may provide 
a substantial degree of protection against serologically dis-
tinct viruses (9). The ability of inﬂ  uenza viruses to mutate 
and reassort their HA-NA genome segments between dif-
ferent animal species is a main concern because immunity 
generated by previous infections or vaccinations is unable 
to prevent infection by itself, although it may reduce virus 
replication and spread (8–10). 
To date, 3 inﬂ  uenza subtypes have produced pandem-
ic disease in humans: H1N1 in 1918, H2N2 in 1957, and 
H3N2 in 1968 (4,11,12). In 1997, during the avian inﬂ  uen-
za (H5N1) outbreak in Hong Kong Special Administrative 
Region, People’s Republic of China, a cross-reactive cellu-
lar immune response induced by inﬂ  uenza (H9N2) was able 
to protect chickens from inﬂ  uenza (H5N1) (13). Moreover, 
adults living in the United States who were never exposed 
to H5N1 subtype have shown cross-type cellular immunity 
to inﬂ  uenza A virus strains derived from swine and avi-
an species (including the H5N1 subtype isolated in Hong 
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Kong) (14). Thus, speculation that cross-reactive T cells 
may decrease illness and death by reducing the replication 
of the new inﬂ  uenza virus, even if elicited by a different 
strain, is reasonable.
Avian inﬂ  uenza A viruses of the H5N1 subtype are 
currently causing widespread infections in bird popula-
tions. Numerous instances of transmission to humans have 
been recently reported in Asia and Africa, with the infection 
resulting in severe disease or death (>50% fatality rate). 
Hence, the aim of the present study was to evaluate the im-
mune cross-reactivity between human and avian inﬂ  uenza 
(H5N1) strains in healthy donors recently vaccinated for 
seasonal inﬂ  uenza A (H1N1/H3N2). Our data indicate that 
inﬂ  uenza vaccination may boost cross-subtype immunity 
against inﬂ  uenza (H5N1), involving cellular or humoral 
responses or both. 
Study Design and Methods
Study Population
Healthcare workers wishing to receive seasonal in-
ﬂ  uenza vaccination at the Spallanzani Institute (n = 42) 
were enrolled. The study was approved by the local Ethical 
Committee; all participants gave written informed consent. 
Baseline characteristics of the study population are reported 
in the Table. Blood samples were obtained before (t0) and 
30 days after vaccination (t1). The vaccine formulation was 
Fluarix, an inactivated and puriﬁ  ed split inﬂ  uenza vaccine 
(GlaxoSmithKline, Verona, Italy). The antigen composi-
tion and strains were A/California/7/2004-H3N2; A/New 
Caledonia/20/99-H1N1; and B/Shanghai/361/2002. Each 
0.5-mL vaccine dose contains 15 μg HA of each strain in 
phosphate-buffered saline and excipients. Vaccine was ad-
ministered intramuscularly.
Cells, Viruses, and Antigens
Madin-Darby-canine kidney (MDCK) cells were 
maintained in Dulbecco modiﬁ  ed Eagle medium (DMEM) 
containing 10% fetal calf serum (FCS), and 2 mmol/L L-
glutamine, at 37°C in a 5% CO2 humidiﬁ  ed atmosphere. 
The inﬂ   uenza (H5N1) virus used was strain A/Hong 
Kong/156/97 (kindly provided by Paul Chan) (15). The 
virus stock used as challenge antigen in the hemagglutina-
tion inhibition (HI) assay was propagated in the allantoic 
cavities of 10-day-old embryonated hen eggs. The allan-
toic ﬂ  uid was harvested 48 h postinoculation and clariﬁ  ed 
by centrifugation. Virus concentration was determined by 
HA titration as previously described (16), and the virus 
was stored at –80°C until used. The virus stock used in the 
microneutralization (NT) and in the cell-mediated immu-
nity assays was propagated in MDCK cells, and the cul-
ture supernatants were collected 48 h postinoculation. The 
50% tissue culture infectious dose (TCID50), determined by 
titration in MDCK cells, was calculated by the Reed and 
Muench method (17).
Inﬂ  uenza vaccine, UV-inactivated MDCK-derived in-
ﬂ  uenza virus (H5N1), or synthetic inﬂ  uenza (H5N1) oligo-
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Table. Baseline characteristics of the study population of 




vaccine receipt Sex Age, y Work position
1 None M 37 Biologist
2 None M 44 Administrative 
personnel
3 None M 42 Administrative 
personnel
4 None F 27 Laboratory 
technician
5 2000–2004 M 45 Physician
6 None F 28 Laboratory 
technician
7 2002–2004 F 45 Nurse
8 2002–2004 M 59 Laboratory 
technician
9 2003–2004 M 52 Laboratory 
technician
10 None M 48 Nurse
11 None M 32 Biologist
12 2000–2004 F 42 Physician
13 2000–2004 F 54 Biologist
14 None M 49 Physician 
15 2000–2004 M 55 Physician 
16 2001–2004 F 42 Nurse
17 None F 40 Biologist
18 None M 38 Biologist
19 None F 34 Physician
20 2004 M 34 Biologist
21 None F 28 Biologist
22 2003–2004 M 59 Physician 
23 2003–2004 F 42 Physician 
24 None M 51 Laboratory 
technician
25 None M 52 Biologist
26 None M 28 Laboratory 
technician
27 2003–2004 F 40 Nurse
28 2003–2004 F 32 Nurse
29 2003–2004 M 35 Biologist
30 None F 51 Laboratory 
technician
31 2003–2004 M 56 Physician 
32 2003–2004 M 36 Physician 
33 None F 32 Nurse
34 2004 M 55 Physician
35 None F 52 Administrative 
personnel
36 2004 M 52 Physician
37 2004 M 49 Nurse
38 2004 F 33 Biologist
39 2002–2004 F 44 Nurse
40 2004 F 43 Nurse
41 2004 M 41 Nurse
42 None M 35 PhysicianCross-subtype Immunity against Avian Inﬂ  uenza
peptides were used as antigens for cell-mediated immunity. 
Inﬂ  uenza virus (H5N1) was inactivated by exposure to UV 
light for 10 min, and complete inactivation of UV-exposed 
virus was checked by infecting MDCK monolayers with 
undiluted preparation and by back-titrating the infectivity 
after 5 days postinfection. Four synthetic peptides of the 
inﬂ  uenza (H5N1) were purchased from Biodesign Inter-
national (Kennebunk, ME, USA). The sequence of these 
peptides is speciﬁ  c for H5-C-terminal (15 aa), H5-middle 
region (14 aa), and N1-C-terminal (15 aa) and for N1-
middle region (16 aa), with no cross-matching with other 
HA and NA sequences. These peptides can bind different 
HLA-DRB1 alleles, as established according to the SYF-
PEITHI site (www.syfpeithi.de). Speciﬁ  cally, N1-speciﬁ  c 
peptides can bind the following HLA-DR alleles: HLA-
DRB1*0101, B1*0301, B1*0401, B1*0701, B1*1101, 
B1*1501. The H5-speciﬁ   c peptide from the N-terminal 
region binds several HLA-DR alleles (HLA-DRB1*0101, 
B1*0301, B1*0401, B1*0701, B1*1101, B1*1501). In 
contrast, the H5-speciﬁ  c peptide from the middle region 
did not appear to bind any HLA-DR alleles. According to 
the HLA-DRB1 allele frequency in the local population, 
these peptides can be efﬁ  ciently presented by most (up to 
84%) of study participants.
Cell-mediated Immunity
Cell-mediated response was assessed by detecting 
intracellular interferon-gamma (IFN-γ) production by ef-
fector T cells, after antigen-speciﬁ  c stimulation in vitro 
to generate effector cells from memory cells (18). Peri-
pheral blood mononuclear cells (PBMC) were isolated 
by density gradient centrifugation (Ficoll-Hypaque, Phar-
macia Biotech, Uppsala, Sweden) and frozen at –150°C. 
Thawed PBMC in culture medium (RPMI 1640, 10% FCS, 
2 mmol/L L-glutamine) were stimulated with the inﬂ  uenza 
vaccine preparation (1.5 μg/mL), UV-inactivated inﬂ  uenza 
(H5N1) (MOI 0.1), or synthetic inﬂ  uenza (H5N1) peptides 
(NA and HA) (1 μg peptide/mL) for 3 days and expanded 
for 6 additional days in the presence of recombinant in-
terleukin-2 (IL-2) (5 IU/mL, Boehringer-Mannheim, 
Mannheim, Germany). On day 9, cells were restimulated 
with the same antigens in the presence of 1 μg/mL αCD28 
and αCD49d (immunoglobulin G1 [IgG1], K clones CD28.2 
and 9f10, respectively; Becton Dickinson, Mountain View, 
CA, USA) and of Brefeldin-A (10 μg/mL, Sigma, St. Lou-
is, MO, USA). As a negative control, a mock virus prepara-
tion, obtained with uninfected MDCK cells, or irrelevant 
peptides were used. To control the spontaneous cytokine 
production, cells incubated with only αCD28 and αCD49d 
were included.
In addition, the frequency of IFN-γ–producing CD4 
T lymphocytes from each donor in the absence of any 
stimulation was used to calculate the background for each 
stimulation. The resulting background levels were very 
low in every experiment, and no differences were observed 
between samples obtained before (t0 0.03% ± 0.04%) and 
after vaccination (t1 0.01% ± 0.03%). The frequency of an-
tigen-speciﬁ  c CD4 T cells for each study participant was 
calculated by subtracting the relative background levels at 
t0 and t1.
Cell-mediated immunity was considered positive when 
the net increase was >0.2%. Although retesting samples 
on separate occasions gave reproducible results, t0 and t1 
samples for each participant were tested simultaneously to 
further reduce test variability.
Immunoﬂ  uorescent Staining 
and Flow Cytometry Analysis
Monoclonal antibodies coupled with phycoerythrin 
(PE), peridinin-chlorophyll protein (PerCP), allophycocya-
nin (APC), and phycoerythrin-Cy-7 (PE-Cy7) were com-
bined for simultaneous staining. In this study the following 
were used: anti-CD4 PerCP (IgG1, clone SK3), anti-CD3 
PE-cy7 (IgG2a, clone SK7), anti-IFN-γ APC (IgG1, clone 
B27), and anti-IL-2 PE (IgG1, clone 5344.111) (Becton 
Dickinson). Cells were stained as previously described (19).
Multiparametric ﬂ  ow cytometry was performed by us-
ing a FACSCanto ﬂ  ow cytometer (Becton Dickinson). A 
total of 300,000 live events were acquired, gated on small 
viable lymphocytes, and analyzed with FACSDiva soft-
ware (Becton Dickinson). The instrument was routinely 
calibrated according to the manufacturer’s instructions.
Microneutralization and HI Assay
The NT was performed according to a previously de-
scribed procedure (20), in agreement with indications from 
the World Health Organization (21) and the US Depart-
ment of Health and Human Services (22). Speciﬁ  cally, 2-
fold serial dilutions of heat-inactivated (30 min at 56°C) 
human sera were performed in 50 μL DMEM without FCS 
in 96-well microplates. An equal volume of inﬂ  uenza virus 
(H5N1) (103 TCID50/mL) was then added to each well. Un-
infected-cell wells, incubated with each test serum, were 
included in each plate as negative controls. After 1 h incu-
bation at 37°C, the mixtures were transferred on MDCK 
cell monolayers and adsorbed at 37°C for 1 h. After wash-
ing, DMEM was added, and the plates were incubated for 2 
days at 37°C in 5% CO2. NT titer was assessed as the highest 
serum dilution in which no cytopathic effect was observed 
by light microscope inspection. All serum specimens were 
tested in duplicate, and t0, and t1 samples from each patient 
were assayed in the same plate at the same time. The results 
were scored by persons blinded to the study participant’s 
identiﬁ  cation. The test results were reproducible because 
random replication of the assays on independent occasions 
gave consistent results.
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The antibody titer was also established by HI test, using 
for challenge either the seasonal vaccine or the egg-derived 
inﬂ  uenza (H5N1) preparation. HI assays were performed in 
V-bottom 96-well plates with 0.5% chicken erythrocytes, 
as described (16).
Biosafety Laboratory Facilities
All experiments with live highly pathogenic avian in-
ﬂ  uenza A virus (H5N1) were conducted by using Biosafety 
Level 3-plus (BSL3+) containment procedures (23). All in-
vestigators were required to wear appropriate masks with 
HEPA ﬁ  lters.
Results
Cell-mediated Immunity to Inﬂ  uenza Viruses
The frequency of circulating antigen-speciﬁ  c CD4 T 
cells in healthy donors enrolled in the study was analyzed 
by ﬂ  ow cytometry, by using intracellular cytokine staining 
assay after the in vitro expansion of effector cells. To gen-
erate effector cells from their memory precursors, PBMC 
were challenged with antigen in vitro for 3 days and ex-
panded for 6 additional days in the presence of IL-2 (18).
Effector cells were characterized for their ability to 
release IFN-γ when cultured overnight in the presence of 
antigen. CD4 T cells were gated and analyzed for IFN-γ 
and IL-2 cytokine expression. A representative experiment 
with PBMC from a recently vaccinated healthy donor is 
shown in Figure 1. Without stimuli, no cytokine produc-
tion in CD4 T cells was detected (Figure 1, panel A). How-
ever, the stimulation with the seasonal inﬂ  uenza vaccine 
preparation induced the production of IFN-γ by CD4 ef-
fector T cells (Figure 1, panel B: 3.2% of IFN-γ+ CD4+ T 
cells). Stimulation with inactivated inﬂ  uenza (H5N1) virus 
induced a CD4 T-cell response (Figure 1, panel C: 1.0% 
of IFN-γ+ CD4+ T cells). Finally, some CD4 T cells spe-
ciﬁ  c for a pool of H5 and N1 (H5/N1) peptides were also 
generated in this donor (Figure 1, panel D: 0.6% of IFN-γ+ 
CD4+ T cells). No IL-2 production was observed in these 
experimental conditions.
Increased Cell-mediated Immunity 
after Seasonal Inﬂ  uenza Vaccination
When the extent of CD4 T-cell–mediated immunity 
before and after seasonal inﬂ  uenza vaccination was com-
pared in the healthy donors enrolled in the study, a non-
homogeneous pattern of responses was detected (online 
Appendix Figure; available from www.cdc.gov/EID/con-
tent/14/1/121-appG.htm. After vaccination (t1), a 2-fold 
variation of the frequency of antigen-speciﬁ  c T cells higher 
than baseline was arbitrarily considered signiﬁ  cant. Ac-
cording to this threshold, an increased frequency of IFN-
γ–producing CD4 T cells speciﬁ  c for vaccine preparation 
was observed after vaccination in 5 (donors 8, 11, 17, 26, 
42) of 21 donors (23.8%). A slight increase of frequency of 
the vaccine preparation-speciﬁ  c CD4 T cells was observed 
in 5 donors (donors 9, 12, 33, 36, 40; 23.8%); a mild-to-
signiﬁ  cant decrease was observed in the remaining donors 
(n = 11; 52.3%).
As shown in the online Appendix Figure, panel A, 
most donors had a detectable level of vaccine preparation–
speciﬁ  c CD4 T cells before vaccination. Six donors (11, 
17, 22, 23, 31, 42) had a noteworthy increase over base-
line of IFN-γ–producing CD4 T cells speciﬁ  c for the H5N1 
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Figure  1. Detection of antigen-speciﬁ  c  CD4 
T cells against inﬂ   uenza viruses by ﬂ  ow 
cytometry after in vitro expansion of effector 
cells. Peripheral blood mononuclear cells 
were expanded in vitro with interleukin-2 
(IL-2) for 9 days in the presence or absence 
of speciﬁ  c  inﬂ   uenza antigens, as indicated, 
then analyzed by ﬂ   ow cytometry by using 
the intracellular staining assay. The effector 
T-cell response was analyzed for interferon- 
gamma (IFN-γ) or IL-2 cytokine expression. 
Unstimulated cultures (A), CD4 T-cell response 
against human inﬂ   uenza vaccine strain 
preparation (B), inactivated avian inﬂ  uenza 
(H5N1) (C), and H5/N1 peptides (D) are shown 
in a representative donor. Cross-subtype Immunity against Avian Inﬂ  uenza
subtype (online Appendix Figure, panel B); among them, 
3 were also showing an increase of the frequency of IFN-
γ–producing CD4 T cells speciﬁ  c for vaccine preparation 
(donors 11, 17, 42). Two of them, donor 11 and donor 42, 
had a signiﬁ  cant increase of IFN-γ–producing CD4 T cells 
speciﬁ  c for H5/N1 peptides (online Appendix Figure, panel 
C), which suggests that cross-type immunity may directly 
involve the HA/NA proteins. Furthermore, 3 other donors 
(donors 12, 16, 36) had an increased frequency of H5/N1 
peptides–speciﬁ  c CD4 T cells, even if they were unable to 
respond to whole virus.
Indeed, in some persons we also observed a signiﬁ  cant 
decrease at t1 in CD4 T cells speciﬁ  c for vaccine prepara-
tion (donors 2, 16, 23, 27, 30, 31, 35, 41), speciﬁ  c for in-
ﬂ  uenza (H5N1) (donors 4, 16, 27), and speciﬁ  c for H5/N1 
peptides (donors 2, 27, 34, 39, 41). Donors with a reduced 
speciﬁ  c response to vaccine preparation at t1 showed a 
higher frequency of speciﬁ  c CD4 T cells at t0 when com-
pared to other donors (3.4% ± 0.88 vs. 1.29% ± 0.35, re-
spectively, p = 0.013). Similar results were obtained when 
we observed the inﬂ  uenza virus (H5N1) (1.07% ± 0.47 
vs. 0.14% ± 0.03, respectively, p = 0.0093) and H5/N1 
peptides (1.19% ± 0.54 vs. 0.13% ± 0.07, respectively; p 
= 0.0018).
H5 versus N1 Speciﬁ  city of the 
Cell-mediated Response
Because some study participants were reactive to inac-
tivated inﬂ  uenza virus (H5N1) as well as to a peptide pool 
composed of 2 peptides from H5 and 2 from N1 consensus 
sequences, we analyzed whether this reactivity was prefer-
entially directed against HA or NA. As shown by PBMC 
from a representative donor in Figure 2, the frequency of 
IFN-γ–producing CD4 effector T cells was appreciable af-
ter challenge with the inactivated inﬂ  uenza virus (H5N1) 
(Figure 2, panel B: 1.82% of IFN-γ+ CD4+ T cells) or with 
the H5/N1 peptides (Figure 2, panel C: 1.52% of IFN-γ+ 
CD4+ T cells). The response of PBMC from the same do-
nor to N1 peptides was positive, whereas the response to 
H5 peptides was at background level (Figure 2, panel E 
and D: 1.49% vs. 0.14% of IFN-γ+ CD4+ T cells), a ﬁ  nding 
that suggests that N1 seems to be the main target for cell-
mediated cross-type immunity against inﬂ  uenza (H5N1) 
and inﬂ  uenza (H3N2)/(H1N1) vaccine strains. A similar 
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Figure 2. H5 versus N1 speciﬁ   city of the cell-mediated response. Proﬁ   ling of inﬂ  uenza  (H5N1)–speciﬁ   c CD4 T-cell response in 
a representative study participant is shown. Peripheral blood mononuclear cells (PBMC) were expanded in vitro in the presence of 
interleukin-2 (IL-2) and stimulated with inactivated inﬂ  uenza (H5N1) virus (B), peptide pool composed by 4 peptides from H5 and N1 (C), 
H5 peptides (D) and N1 peptides (E). Panel A shows unstimulated cultures. Dot plots showed the presence, at similar frequency, of speciﬁ  c 
CD4 T cells when PBMC were stimulated with inactivated inﬂ  uenza (H5N1) virus (panel B, 1.82%), inﬂ  uenza (H5N1) peptides (panel C, 
1.52%), and N1 peptides (panel E, 1.49%). No speciﬁ  c CD4 T cells producing interferon-gamma (IFN-γ) were observed after challenge 
with H5 peptides (D). As negative control, either mock-infected culture supernatants or irrelevant peptides were used, giving results very 
similar to unstimulated cultures (not shown). A similar pattern was observed in 4 other study participants, supporting the hypothesis that 
the actual target of cross-subtype immunity could be N1.RESEARCH
pattern was observed in 4 other study participants, which 
supports the hypothesis that the target of cross-subtype im-
munity could actually be N1.
Increased Humoral Immunity 
after Seasonal Inﬂ  uenza Vaccination
Human sera from the same donors were tested for HI 
activity against both vaccine and inﬂ  uenza (H5N1) prepa-
rations and for neutralization activity against inﬂ  uenza 
(H5N1) virus. Individual titers are reported in Figure 3. A 
4-fold rise in HA antibody titer is considered noteworthy, 
and after vaccination most donors (28/38; 73.7%) showed 
a noteworthy rise of HI titers against vaccine preparation, 
as indicated by an asterisk (Figure 3, top panel, black bars). 
HI titers against inﬂ  uenza virus (H5N1) remained at unde-
tectable levels after seasonal vaccination (data not shown), 
but a rise of neutralization titer >20-fold over baseline was 
observed in 13 (34.2%) of 38 donors (Figure 3, bottom 
panel, asterisk). All but 1 study participant also responded 
to seasonal vaccination by a rise in HI titers against vaccine 
preparation. One donor (21) showed high titers against the 
H5N1 subtype in NT but a low HI titer against vaccine, a 
unique situation in the study population. However, antibod-
ies to both anti–inﬂ  uenza (H5N1) and inﬂ  uenza vaccine are 
raised by vaccination. Our ﬁ  ndings indicate that seasonal 
vaccination can raise neutralizing immunity against inﬂ  u-
enza (H5N1), which shows the existence of an antibody-
dependent cross-type immunity. No correlation between 
inﬂ  uenza-speciﬁ  c CD4 T cells and humoral responses was 
observed, which suggests that this type of antibody re-
sponse was mainly CD4 T-cell independent.
Discussion
We observed that inﬂ  uenza-speciﬁ  c CD4-effector T 
cells could be generated by long-term cultures in vitro and 
easily monitored by ﬂ  ow cytometry as IFN-γ–producing 
cells. When this approach was used, a small frequency of 
CD4 T cells speciﬁ  c for H5N1 subtype could be detected 
in several persons at baseline. Seasonal vaccine administra-
tion may enhance the frequency of reactive CD4 T cells, 
boosting the cross-subtype cellular immunity against avian 
inﬂ  uenza (H5N1). We also observed that seasonal vaccina-
tion raised neutralizing immunity against H5N1 subtype in 
a large number of donors, showing the existence of an anti-
body-dependent cross-type immunity. Thus, cross-reactive 
immunity may involve cellular and/or humoral responses, 
but the humoral response seems to be CD4 independent.
From the present data, N1 appears to be 1 target for 
cross-type cellular immunity, although we could not rule 
out the involvement of different (i.e., internal) antigens as 
possible targets of immune recognition by effector CD4 T 
cells. Nevertheless, in animal models, cellular immunity 
(mainly CLT) targeting internal proteins (i.e., NP), partly 
responsible for heterosubtypic protection, was not induced 
efﬁ  ciently by inactivated vaccines (24). We did not use live 
virus, only inactivated split vaccine, whole inactivated vi-
rus, or HA and NA peptides for the inﬂ  uenza (H5N1) A/
Hong-Kong/156/97 strain. From our data, discriminating 
between the CD4 T-cell response against external or inter-
nal antigens in the case of vaccine preparation was not pos-
sible. For H5N1 subtype response, we can presume that the 
response is against the external antigens and that the results 
against peptides point to a speciﬁ  c response against NA. 
Results obtained with the whole virus and those ob-
tained with the H5 and N1 peptides are not in complete 
agreement (online Appendix Figure). This ﬁ  nding can be 
explained on the basis of the substantial differences in the 
antigen presentation underlying the whole virus and pep-
tides. Moreover, we observed that a high activation of spe-
ciﬁ  c cells at baseline (t0) was associated with a reduced 
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Figure 3. Humoral response against vaccine 
preparation and inﬂ   uenza virus (H5N1) 
before (t0) and after (t1) seasonal inﬂ  uenza 
vaccination. Hemagglutination inhibition (HI) 
test was used to calculate the antibody (Ab) 
titer against vaccine preparation (top panel), 
whereas a neutralization test was used to 
calculate the antibody titer against inﬂ  uenza 
(H5N1) (bottom panel) in healthy donors 
enrolled in the study at baseline (t0) and 1 
month after seasonal inﬂ  uenza  vaccination 
(t1). At baseline (white bars), all donors had a 
detectable level of human inﬂ  uenza antibodies. 
At t1 (black bars), 28 donors (73.6%) 
(indicated by *) showed a >4 fold increase 
of Ab titer against vaccine preparation (HI) 
over t0. After seasonal inﬂ  uenza vaccination, 
13 serum samples (33.3%) (indicated by *) 
from the study population showed a 20-fold 
increase of neutralizing Abs against inﬂ  uenza 
(H5N1) over t0.Cross-subtype Immunity against Avian Inﬂ  uenza
speciﬁ  c response after vaccination (t1), which suggests that 
stimulation of pre-activated T cells with high dose of anti-
gen could induce T-cell anergy (25) with consequent loss 
of immune response.
Preliminary evidence also suggests that humoral cross-
type immunity is targeting antigens differently from HA: 
sera from persons showing signiﬁ  cant neutralizing titers 
against inﬂ  uenza (H5N1) did not recognize insect cells ex-
pressing HA from the H5N1 subtype (not shown) and did 
not show HI activity against H5N1 subtype. N1 may pos-
sibly also be a target of humoral immunity, but additional 
experiments such as Western blot analysis or inhibition of 
NA activity (26) are needed to clarify this point.
In animals, exposure to 1 speciﬁ  c subtype of inﬂ  uenza 
A virus can also induce protective immunity against chal-
lenges with other subtypes. This heterosubtypic or cross-
protective immunity could represent a key mechanism for 
facing, and limiting, new inﬂ  uenza outbreaks. In 1997, dur-
ing the Hong Kong inﬂ  uenza (H5N1) outbreak, an immune 
response induced by an inﬂ  uenza virus (H9N2), being T 
cells but not antibodies, protected chickens from lethal in-
ﬂ  uenza (H5N1) (13). Moreover, adults living in an urban 
area of the United States have been described as having 
inﬂ  uenza-speciﬁ  c memory T cells that recognize epitopes 
of inﬂ  uenza A virus strains derived from swine and avian 
species, including the inﬂ  uenza (H5N1) strain involved in 
the Hong Kong outbreak in humans (14).
Our data conﬁ  rm that persons who have never been ex-
posed to H5N1 subtype may be able to generate a cell-me-
diated response against the Hong Kong inﬂ  uenza (H5N1) 
isolate. This cross-type response may be naturally occur-
ring (probably as a consequence of exposure to seasonal 
inﬂ  uenza strains).
In mice, both CD4 T-cell–independent and –dependent 
antibody responses contribute to the control of inﬂ  uenza 
virus infection (27,28). Although antibodies appear to fa-
cilitate the recovery from inﬂ  uenza infection, it is generally 
believed that B cells cannot produce neutralizing, isotype-
switched, inﬂ  uenza-speciﬁ  c antibodies in the absence of 
CD4 T-cell help (29,30). However, other data clearly dem-
onstrate that B cells can also produce anti-inﬂ  uenza IgA, 
IgM, and IgG responses independent of CD4 helper T cells 
(27,31). A non–antigen-speciﬁ  c bystander response driven 
by activated CD4 T cells speciﬁ  c for heterologous anti-
gen may contribute to so-called heterosubtypic immunity 
(8–10,12). However, the ability of inﬂ  uenza virus infection 
to promote B-cell activation and differentiation into short-
lived, isotype-switched, antibody-secreting cells may result 
from a combination of B-cell receptor hypercross-linking, 
engagement of toll-like receptors, production of cytokines, 
as well as triggering of innate immunity.
In our study, cellular and humoral cross-reactive im-
munity seemed to target antigens other than HA. Inﬂ  uenza 
(H5N1) cases occur mainly in young people (32). This ﬁ  nd-
ing may be explained by hypothesizing that older people, 
although not previously exposed to H5N1 subtype, may 
have gained protective immunity by previous infections 
sustained by circulating inﬂ  uenza virus strains. It has also 
been shown that immunity to the N1 NA from the human 
inﬂ  uenza virus cross-reacts with the avian N1 NA virus 
and that this cross-reactivity protects mice against infection 
with the avian inﬂ  uenza virus (H5N1) (26). All these ﬁ  nd-
ings may be explained by hypothesizing that cross-reactive 
immunity is targeting the N1 NA antigen. However, wheth-
er cross-reactive antibodies to NA and CD4 T cells would 
be protective against illness and death, especially from in-
ﬂ  uenza (H5N1) infection is not known. Further studies will 
be necessary to elucidate this point.
In conclusion, we demonstrated that vaccination 
against seasonal inﬂ  uenza may boost a cross-reactive im-
munity against an unrelated strain responsible for deadly 
infections in humans, i.e., the avian inﬂ  uenza (H5N1) strain 
A/Hong Kong/156/97. These data, together with previous 
experimental results from mice studies and epidemiologic 
reports, indicate that cross-type immunity should be con-
sidered an important component of the immune response 
against novel inﬂ  uenza A infections.
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